Clinical Trial Simulations for Dosage Optimization of Docetaxel in Patients with Liver Dysfunction, Based on a Log-binominal Regression for Febrile Neutropenia-Reference-Cited by-同舟云学术

Clinical Trial Simulations for Dosage Optimization of Docetaxel in Patients with Liver Dysfunction, Based on a Log-binominal Regression for Febrile Neutropenia

Published:2009-06-01 Issue:6 Volume:129 Page:749-757
ISSN:0031-6903
Container-title:YAKUGAKU ZASSHI
language:en
Short-container-title:YAKUGAKU ZASSHI

Author:

OZAWA Kazuhiro¹,MINAMI Hironobu²³,SATO Hitoshi¹

Affiliation:

1. Department of Clinical and Molecular Pharmacokinetics/Pharmacodynamics, School of Pharmaceutical Sciences, Showa University

2. The Division of Oncology/Hematology, National Cancer Center Hospital East

3. Medical Oncology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology

Link

https://www.jstage.jst.go.jp/article/yakushi/129/6/129_6_749/_pdf

Reference24 articles.

1. 1) Jones S. E., Savin M. A., Holmes F. A., O'Shaughnessy J. A., Blum J. L., Vukelja S., McIntyre K. J., Pippen J. E., Bordelon J. H., Kirby R., Sandbach J., Hyman W. J., Khandelwal P., Negron A. G., Richards D. A., Anthony S. P., Mennel R. G., Boehm K. A., Meyer W. G., Asmar L., J. Clin. Oncol., 24, 5381-5387 (2006).

2. 2) Bear H. D., Anderson S., Brown A., Smith R., Mamounas E. P., Fisher B., Margolese R.,Theoret H., Soran A., Wickerham D. L., Wolmark N., J. Clin. Oncol., 21, 4165-4174 (2003).

3. 3) Georgoulias V., Ardavanis A., Tsiafaki X., Agelidou A., Mixalopoulou P., Anagnostopoulou O., Ziotopoulos P., Toubis M., Syrigos K., Samaras N., Polyzos A., Christou A., Kakolyris S., Kouroussis C., Androulakis N., Samonis G., Chatzidaki D., J. Clin. Oncol., 23, 2937-2945 (2005).

4. 4) Georgoulias V., Ardavanis A., Agelidou A., Agelidou M., Chandrinos V., Tsaroucha E., Toumbis M., Kouroussis C., Syrigos K., Polyzos A., Samaras N., Papakotoulas P., Christofilakis C., Ziras N., Alegakis A., J. Clin. Oncol., 22, 2602-2609 (2004).

5. 5) Vasey P. A., Jayson G. C., Gordon A., Gabra H., Coleman R., Atkinson R., Parkin D., Paul J., Hay A., Kaye S. B., J. Natl. Cancer Inst., 96, 1682-1691 (2004).

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical application of the AUC-guided dosage adjustment of docetaxel-based chemotherapy for patients with solid tumours: a single centre, prospective and randomised control study;Journal of Translational Medicine;2020-06-08

2. Pharmacokinetics, Food Effect, Ketoconazole Interaction, and Safety of JTK‐853, a Novel Nonnucleoside HCV Polymerase Inhibitor, After Ascending Single and Multiple Doses in Healthy Subjects;Clinical Pharmacology in Drug Development;2019-02-19

3. Receiver Operating Characteristic Analysis and Clinical Trial Simulation to Inform Dose Titration Decisions;CPT: Pharmacometrics & Systems Pharmacology;2018-10-15

4. Optimizing drug development in oncology by clinical trial simulation: Why and how?;Briefings in Bioinformatics;2017-05-29

5. Outcomes of Dose-Attenuated Docetaxel in Asian Patients with Castrate-Resistant Prostate Cancer;Annals of the Academy of Medicine, Singapore;2017-05-15